NLS Pharmaceutics announced that the United States Patent and Trademark Office, or USPTO, has issued a Notice of Allowance for U.S. Patent Application 16/645,306, which covers Mazindol as a method of treatment for heroin dependence and substance use disorders comprising administering mazindol or composition comprising mazindol to a subject, wherein the substance is an opioid and Mazindol is administered daily at a daily dosage range from between 3 mg and 16 mg. NLS expects this patent to be issued within the next few months and it is expected to expire no earlier than 2038.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on NLSP:
